All tenders
75A50124C00061
PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFFICACY, AS WELL AS ADVANCE DEVELOPMENT OF MONOCYTE HUMAN LEUKOCYTE ANTIGEN-DR (MHLA-DR) AS
Office of Assistant Secretary for Preparedness and Response · United States
This tender closed on Friday, March 31, 2028. Browse open opportunities
Time Left to Bid
Closed
ClosedOtherFederal
Basic information
- Reference number
- 75A50124C00061
- Issuing organization
- Office of Assistant Secretary for Preparedness and Response · Find award history →
- Government level
- Federal
- Solicitation type
- Other
- Title
- PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFFICACY, AS WELL AS ADVANCE DEVELOPMENT OF MONOCYTE HUMAN LEUKOCYTE ANTIGEN-DR (MHLA-DR) AS
- Source
- USASpending (Federal)
- Source ID
- usa-75A50124C00061
Details
- Location
- United States
Description
PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFFICACY, AS WELL AS ADVANCE DEVELOPMENT OF MONOCYTE HUMAN LEUKOCYTE ANTIGEN-DR (MHLA-DR) AS Awarded to: PARTNER THERAPEUTICS, INC. Agency: Department of Health and Human Services Sub-agency: Office of Assistant Secretary for Preparedness and Response Award type: DEFINITIVE CONTRACT
Dates
- Publication
- 2024/09/30 12:00:00 AM UTC
- Closing date
- 2028/03/31 12:00:00 AM UTC
Estimated value
$13.0M USD
Classification
Normalized category
Other